Telbolife LN 80 Tablet contains Telmisartan 80 mg + Cilnidipine 10 mg, a powerful dual-action anti-hypertensive combination used for management of moderate to severe high blood pressure.
Telmisartan blocks angiotensin II receptors to reduce vascular resistance, while Cilnidipine relaxes blood vessels by dual L- and N-type calcium channel blockade, ensuring smooth, sustained BP reduction.
Clinically, this combination is preferred for patients with uncontrolled hypertension, offering once-daily dosing, better tolerance, and improved compliance.
From a business standpoint, Telbolife LN 80 Tablet strengthens the cardiac and hypertension therapy segment, delivering strong prescription demand, repeat sales, and profitable PCD pharma franchise potential at a best price for franchise partners.
Common side effects may include dizziness, headache, flushing, ankle edema, or fatigue. Rarely, hypotension, palpitations, or gastrointestinal discomfort may occur.
Telbolife LN 80 Tablet is indicated for the management of essential hypertension, particularly in patients who require combination therapy to achieve adequate blood pressure control. It is beneficial for patients not sufficiently controlled on monotherapy.
Use Telbolife LN 80 Tablet only under medical supervision. Blood pressure should be monitored regularly during treatment. Use with caution in patients with renal impairment, dehydration, or electrolyte imbalance. Do not stop the medication abruptly without consulting a healthcare professional.
Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight, and keep out of reach of children. Do not use beyond the expiry date.